AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Nov 21, 2025, 9:06 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The significant drop in share price indicates strong negative investor sentiment. Historical precedents show that similar legal disputes often lead to prolonged stock underperformance.
AI summary
What happened, with direct paths to the underlying reporting
AnaptysBio shares dropped 14% amid lawsuits with Tesaro over a partnership breach. Both companies claim breach of partnership in a cancer drug deal.
AnaptysBio shares dropped 14% amid lawsuits with Tesaro over a partnership breach.
Both companies claim breach of partnership in a cancer drug deal.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
AnaptysBio and GSK's Tesaro are engaged in a legal dispute. The lawsuit concerns breaches related to their Jemperli drug partnership. AnaptysBio's shares fell 14% in premarket tra…
GSK's Tesaro files litigation against AnaptysBio for license agreement breaches. A ruling may allow Tesaro to terminate AnaptysBio's dostarlimab license. Dostarlimab is approved i…
Rosnilimab failed to meet primary efficacy endpoints in ulcerative colitis trial. Phase 2 trial discontinuation may save AnaptysBio over $10 million. Rosnilimab showed safety but…